MX339765B - Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal. - Google Patents

Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.

Info

Publication number
MX339765B
MX339765B MX2012008955A MX2012008955A MX339765B MX 339765 B MX339765 B MX 339765B MX 2012008955 A MX2012008955 A MX 2012008955A MX 2012008955 A MX2012008955 A MX 2012008955A MX 339765 B MX339765 B MX 339765B
Authority
MX
Mexico
Prior art keywords
renal
prognosis
diagnosis
compositions
methods
Prior art date
Application number
MX2012008955A
Other languages
English (en)
Other versions
MX2012008955A (es
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2012008955A publication Critical patent/MX2012008955A/es
Publication of MX339765B publication Critical patent/MX339765B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/524—Thrombopoietin, i.e. C-MPL ligand
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para supervisar, diagnosticar, pronosticar, y determinar regímenes de tratamiento en sujetos que sufren de o se sospecha tienen una lesión renal. Particularmente, la invención se refiere a usar uno o más ensayos configurados para detectar un marcador de lesión del riñón seleccionado del grupo que consiste delnterleucina-5, subunidad beta del receptor de Interleucina-6, factor de tejido, globulina que liga a hormona del sexo, Alfa-2-macroglobulina, Apolipoproteína A-I, Calcitonina, Trombopoyetina, proteína C-reactiva, molécula de adhesión intercelular 3, metalloelastasa de macrófago, Apolipoproteína B-100, y fibrinógeno como biomarcadores de diagnóstico y pronóstico en lesiones renales.
MX2012008955A 2010-02-05 2011-02-04 Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal. MX339765B (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US30201210P 2010-02-05 2010-02-05
US30197010P 2010-02-05 2010-02-05
US30198510P 2010-02-05 2010-02-05
US30203210P 2010-02-05 2010-02-05
US30199210P 2010-02-05 2010-02-05
US30203910P 2010-02-05 2010-02-05
US30204510P 2010-02-05 2010-02-05
US30204710P 2010-02-05 2010-02-05
US30201610P 2010-02-05 2010-02-05
US30198110P 2010-02-05 2010-02-05
US30200910P 2010-02-05 2010-02-05
US30196110P 2010-02-05 2010-02-05
US30204810P 2010-02-05 2010-02-05
PCT/US2011/023832 WO2011097541A2 (en) 2010-02-05 2011-02-04 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
MX2012008955A MX2012008955A (es) 2012-11-23
MX339765B true MX339765B (es) 2016-06-08

Family

ID=44356097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008955A MX339765B (es) 2010-02-05 2011-02-04 Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.

Country Status (11)

Country Link
US (1) US20130230871A1 (es)
EP (1) EP2531622B1 (es)
JP (2) JP5998055B2 (es)
CN (1) CN102884205B (es)
AU (1) AU2011213686B2 (es)
CA (1) CA2788829A1 (es)
EA (1) EA201290627A1 (es)
HK (1) HK1174367A1 (es)
MX (1) MX339765B (es)
NZ (1) NZ601648A (es)
WO (1) WO2011097541A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078736A2 (en) * 2010-12-09 2012-06-14 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
JP2017513009A (ja) 2014-04-09 2017-05-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫評価および移植片拒絶の予測のためのタンパク質バイオマーカー
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
GB201511207D0 (en) * 2015-06-25 2015-08-12 Xvivo Perfusion Ab Isolated organ evaluation and treatment
CN114778845A (zh) 2016-03-29 2022-07-22 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
US12091701B2 (en) 2016-03-29 2024-09-17 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
JPH02275359A (ja) * 1989-04-18 1990-11-09 Teijin Ltd 腎疾患の診断方法、診断試薬およびキット
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
EP0585310B1 (en) 1991-04-10 1999-03-17 Biosite Diagnostics Inc. Crosstalk inhibitors and their uses
ES2150915T3 (es) 1991-04-12 2000-12-16 Biosite Diagnostics Inc Nuevos conjugados y dosificados destinados para la deteccion simultanea de ligandos multiples.
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US20090258002A1 (en) * 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
WO2008084331A2 (en) * 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2469282A1 (en) * 2006-09-08 2012-06-27 University of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US8592170B2 (en) * 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease

Also Published As

Publication number Publication date
WO2011097541A3 (en) 2011-11-10
EA201290627A1 (ru) 2013-05-30
AU2011213686A1 (en) 2012-08-30
CA2788829A1 (en) 2011-08-11
JP2013519866A (ja) 2013-05-30
MX2012008955A (es) 2012-11-23
JP2016006430A (ja) 2016-01-14
CN102884205A (zh) 2013-01-16
NZ601648A (en) 2015-05-29
EP2531622A4 (en) 2013-07-17
US20130230871A1 (en) 2013-09-05
HK1174367A1 (zh) 2013-06-07
EP2531622A2 (en) 2012-12-12
WO2011097541A2 (en) 2011-08-11
JP6186400B2 (ja) 2017-08-23
JP5998055B2 (ja) 2016-09-28
EP2531622B1 (en) 2016-04-06
CN102884205B (zh) 2016-05-04
AU2011213686B2 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
MX339765B (es) Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
EP3070474A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2585827A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX2011004767A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2813848A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
EP2811036A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ796092A (en) Methods for detecting signatures of disease or conditions in bodily fluids
MX2014000283A (es) Metodos y composiciones para diagnóstico y pronóstico de lesión e insuficiencia renal.
MX342967B (es) Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
EP2585826A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE
WO2013067495A3 (en) Personal spirometer
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112015014232A2 (pt) lesão renal aguda
NZ605640A (en) Signal biomarkers
WO2011158016A3 (en) Assay
WO2012167887A8 (en) Diagnostic use of prosomatostatin
MX2011007810A (es) Biomarcadores asociados con nefropatia.
WO2012040264A3 (en) Diagnostic tests for immune reactivity with human endothelial cell growth factor

Legal Events

Date Code Title Description
FG Grant or registration